Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 826503, 5 pages
http://dx.doi.org/10.1155/2014/826503
Review Article

Promise and Challenge: The Lens Model as a Biomarker for Early Diagnosis of Alzheimer's Disease

1Department of Neurology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China
2Department of Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China

Received 28 June 2013; Revised 24 December 2013; Accepted 6 January 2014; Published 12 February 2014

Academic Editor: Tori L. Schaefer

Copyright © 2014 Tian Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Alzheimer’s disease (AD) is the most common form of dementia pathologically characterized by cerebral amyloid-beta (A ) deposition. Early and accurate diagnosis of the disease still remains a big challenge. There is evidence that A aggregation starts to occur years before symptoms arise. Noninvasive monitoring of A plaques is critical for both the early diagnosis and prognosis of AD. Presently, there is a major effort on looking for a reasonably priced technology capable of diagnosing AD by detecting the presence of A . Studies suggest that AD is systemic rather than brain-limited focus diseases and the aggregation of the disease-causing proteins also takes place in lens except the brain. There is a possible relationship between AD and a specific subtype of age-related cataract (supranuclear cataract). If similar abnormal protein deposits are present in the lens, it would facilitate non-invasive diagnosis and monitoring of disease progression. However, there are controversies on the issues related to performance and validation of A deposition in lens as biomarkers for early detection of AD. Here we review the recent findings concerning A deposition in the lenses of AD patients and evaluate if the ocular lens can provide a biomarker for AD.